C
Climb Bio, Inc.
CLYMCIK 0001768446NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-59.85M
Total Assets
$167.74M
Equity
$160.47M
Shares Out
47.77M
Op. Cash Flow
$-54.36M
Business
Climb Bio, Inc. is a clinical-stage biotechnology company developing targeted monoclonal antibody therapeutics for immune-mediated diseases. Its main product candidates are budoprutug, a clinical-stage anti‑CD19 monoclonal antibody designed to deplete CD19‑expressing B cells, and CLYM116, a preclinical anti‑APRIL monoclonal antibody targeting APRIL signaling. The company’s operations focus on research and development, clinical development programs, formulation (IV and subcutaneous), and in‑licensing/partnership arrangements. Climb Bio pursues worldwide development and commercialization rights for budoprutug (excluding oncology) and rights to develop and commercialize CLYM116 outside Greater China, relying on clinical trial sites, contract development and manufacturing organizations, and potential commercial partners for distribution.
Summary from filing dated 2025-03-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Acquired in-process research and development, related party | 0 | 52 | — | — | — | |
| Research and development expense | 47 | 14 | 15 | 26 | 23 | |
| General and administrative | 21 | 16 | 25 | 19 | 12 | |
| Total operating expenses | 68 | 82 | 40 | 45 | 36 | |
| Total loss from operations | −68 | −82 | −40 | −45 | −36 | |
| Foreign currency loss | −291,000 | −9,000 | — | — | — | |
| Interest income | 8 | 8 | — | — | — | |
| Total other income (expense) | 8 | 8 | 5 | −109,000 | −12 | |
| Net loss | −60 | −74 | −35 | −45 | −47 | |
| Net loss per share, diluted | −0.88 | −1.53 | −1.3 | −1.72 | −4.24 | |
| Net loss per share, basic | −0.88 | −1.53 | −1.3 | −1.72 | −4.24 | |
| Weighted-average number of shares used to compute net loss per share, diluted | 68 | 48 | 27 | 26 | 12 | |
| Weighted-average number of shares used to compute net loss per share, basic | 68 | 48 | 27 | 26 | 12 | |
| Unrealized gain on marketable securities | 412,000 | 25,000 | — | — | — | |
| Comprehensive loss | −59 | −74 | −35 | −45 | −48 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 36 | 87 | 93 | 44 | 47 | |
| Short-term marketable securities | 65 | 64 | 14 | 80 | 90 | |
| Prepaid expenses and other current assets | 5 | 4 | 3 | 11 | 12 | |
| Total current assets | 106 | 155 | 110 | 134 | 148 | |
| Long-term marketable securities | 60 | 62 | 0 | 0 | 25 | |
| Operating lease right-of-use assets | 505,000 | 490,000 | 199,000 | 471,000 | 0 | |
| Property and equipment, net | 288,000 | 199,000 | — | — | — | |
| Other long-term assets | 2 | 16,000 | 15,000 | 128,000 | 70,000 | |
| Total assets | 168 | 217 | 110 | 135 | 173 | |
| Accounts payable | 2 | 705,000 | 66,000 | 750,000 | 1 | |
| Accrued expenses and other current liabilities | 4 | 4 | — | — | — | |
| Operating lease liabilities | 256,000 | 157,000 | 334,000 | 300,000 | 0 | |
| Total current liabilities | 7 | 5 | 3 | 6 | 6 | |
| Operating lease liabilities, net of current portion | 285,000 | 375,000 | 15,000 | 180,000 | 0 | |
| Total liabilities | 7 | 5 | 3 | 6 | 6 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5,000 | 7,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 450 | 442 | 264 | 250 | 243 | |
| Accumulated other comprehensive income | 435,000 | 23,000 | −2,000 | −358,000 | −123,000 | |
| Accumulated deficit | −290 | −230 | −156 | −121 | −76 | |
| Total stockholders' equity | 160 | 212 | 108 | 129 | 167 | |
| Total liabilities and stockholders' equity | 168 | 217 | 110 | 135 | 173 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −60 | −74 | — | — | — | |
| Stock-based compensation expense | 8 | 6 | 13 | 7 | 4 | |
| Non-cash operating lease expense | 201,000 | 220,000 | 405,000 | 443,000 | 0 | |
| Accretion of discounts on marketable securities, net | −2 | −757,000 | −2 | −177,000 | 370,000 | |
| Depreciation and amortization expense | 97,000 | 0 | — | — | — | |
| Unrealized foreign currency transaction (gain) loss | 18,000 | −42,000 | — | — | — | |
| Prepaid expenses and other current assets | −816,000 | 2 | 7 | 945,000 | −10 | |
| Other long-term assets | −2 | −200,000 | — | — | — | |
| Accounts payable | 2 | −963,000 | −686,000 | −653,000 | 318,000 | |
| Accounts payable and accrued liabilities, related party | 0 | −177,000 | 0 | — | — | |
| Accrued expenses and other current liabilities | 372,000 | 1 | — | — | — | |
| Operating lease liabilities | −207,000 | −327,000 | −444,000 | −447,000 | 0 | |
| Long-term liabilities | 0 | −22,000 | — | — | — | |
| Net cash used in operating activities | −54 | −16 | −21 | −37 | −36 | |
| Purchases of property and equipment | −186,000 | 0 | — | — | — | |
| Purchase of marketable securities | −108 | −132 | −58 | −88 | −115 | |
| Maturities of marketable securities | 111 | 21 | 127 | 122 | 0 | |
| Issuance of promissory loan in connection with asset acquisition | 0 | −5 | — | — | — | |
| Cash paid in connection with asset acquisition, net of cash received | 0 | −5 | — | — | — | |
| Net cash provided by (used in) investing activities | 3 | −121 | 69 | 34 | −115 | |
| Proceeds from exercise of stock options | 65,000 | 11 | — | — | — | |
| Pre-funded warrant issuance costs | −86,000 | 0 | — | — | — | |
| Proceeds from issuance of common stock in private placement, net of issuance costs | 0 | 120 | — | — | — | |
| Net cash provided by (used in) financing activities | −21,000 | 131 | 841,000 | 0 | 177 | |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 42,000 | 304,000 | −408,000 | 245,000 | |
| Net change in cash and cash equivalents | −52 | −6 | 50 | −3 | 26 | |
| Issuance of common stock in exchange for in-process research and development | 0 | 42 | — | — | — | |
| Settlement of promissory loan in connection with asset acquisition | 0 | 5 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro